Clinical Trial: Randomized Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07011719) titled 'Randomized Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma' on June 02.

Brief Summary: The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced progression on or after prior anti-PD-1 or anti-PD-L1 immunotherapy.

Study Start Date: July, 2025

Study Type: INTERVENTIONAL

Condition: Metastatic Clear Cell Renal Cell Carcinoma Advanced Clear Ce...